Navelbine Articles
Novartis' Afinitor may overcome Herceptin resistance; Ph I study
22 December 2008
Operating income up 21% at Kyowa Hakko
4 February 2008
Hana's Alocrest displays efficacy in solid tumor trial
5 November 2007
Kyowa Hakko's fiscal 2006 profit falls 22%
7 May 2007
Kyowa's net income falls 47.5% to 3.9B yen
6 November 2006
Canadian provinces OK Genentech's Herceptin
1 August 2005
Cell Thera's Xyotax sees strong Ph III results
18 July 2005
Pierre Fabre to retain independence
7 July 2003
NY claims of Rx overcharging could lead to industry-wide probe
24 February 2003
FDA turns down early Casodex use
1 July 2002
France clears oral form of vinorelbine
5 April 2001
Euro NSCLC market sees renewed growth
21 March 2001
BioMerieux-Pierre Fabre and Celera forge link
30 January 2001
Pierre Fabre to focus on natural substances
9 January 2001
Cell Pathways and GW hook up for cancer study
20 July 2000
Fabre collaboration with Glaxo Wellcome
11 January 2000
Cell Genesys gets $4.5m payment for GVAX cancer vaccine
13 December 1999
France's Pierre Fabre to manufacture Taxotere for R-PR
9 December 1999
Xenova's INDA for XR9576
26 November 1999
Pierre Fabre buys stake in SA drug firm
28 July 1999
More Approvals For Pierre Fabre's Navelbine
20 March 1998
Pierre Fabre Launches Navelbine In The UK
30 May 1997
Glaxo Wellcome 1996 Product Performance
17 March 1997
Launch Of Glaxo Wellcome's Navelbine In Canada
17 June 1996
Suramin Disappoints In Prostate Cancer
6 May 1996
Fabre To Focus Production At Its Gien Site
7 August 1995
Pierre Fabre Out Of The Red In 1994
24 April 1995
Higher Sales Boost Profits At Kyowa Hakko
3 April 1995
Robb Claims Wellcome Is Undervalued By Glaxo
20 February 1995
Fabre Ambitions In German Market
23 January 1995
FDA Approves BW's Lamictal
9 January 1995
European Stock Comment
9 January 1995
Navelbine Approvable In USA
12 December 1994
NAVELBINE APPROVED IN CANADA
23 May 1994
NAVELBINE NEARING APPROVAL IN USA
9 May 1994
WELLCOME RECEIVES RECOMMENDATION
24 January 1994
NAVELBINE RECOMMENDED FOR APPROVAL
20 December 1993
PIERRE FABRE SECURES FUTURE
2 August 1993
CANCER MEDICINES IN DEVELOPMENT
14 June 1993
WELLCOME REFOCUSING R&D EFFORTS
10 May 1993
BREAST CANCER US RESEARCH UPDATE
26 April 1993
WELLCOME'S US "TIDAL WAVE" REVERSING?
21 December 1992
WELLCOME PRETAX PROFITS RISE 25%
2 November 1992
NEW CANCER DRUGS SHINE AT US MEETING
2 November 1992
KYOWA HAKKO KOGYO: R&D PROJECTS
25 May 1992
Showing 1-53 of 53 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
